Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamet...
Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema
About this item
Full title
Author / Creator
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundThe BEVORDEX trial compared outcomes of eyes with diabetic macular oedema (DMO) randomised to receive either intravitreal dexamethasone (DEX-) implant or bevacizumab over 2 years. We assessed long-term efficacy and safety outcomes 5 years from enrolment.MethodsPatients received standard clinical care after they finished the study. Their f...
Alternative Titles
Full title
Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9763198
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9763198
Other Identifiers
ISSN
0007-1161
E-ISSN
1468-2079
DOI
10.1136/bjophthalmol-2021-319839
